Trials / Active Not Recruiting
Active Not RecruitingNCT04613557
Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma
Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory Disease
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Celyad Oncology SA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide
Detailed description
This study aims to determine the recommended dose of the allogeneic CYAD-211 (anti-BCMA CAR-T) cells after a non-myeloablative preconditioning chemotherapy in multiple myeloma (MM) patients with relapsed or refractory disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CYAD-211 | Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell |
| DRUG | Endoxan | Preconditioning chemotherapy |
| DRUG | Fludara | Preconditioning chemotherapy |
Timeline
- Start date
- 2020-11-16
- Primary completion
- 2022-12-21
- Completion
- 2037-02-01
- First posted
- 2020-11-03
- Last updated
- 2023-08-31
Locations
5 sites across 2 countries: United States, Belgium
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04613557. Inclusion in this directory is not an endorsement.